Want to see HSCS full AI Analyst Report?
HSCS Stock Chart & Stats
$3.00
-$0.05(-2.05%)
At close: 4:00 PM EDT
$3.00
-$0.05(-2.05%)
Day’s Range― - ―
52-Week Range$1.63 - $3.83
Previous CloseN/A
Volume8.21K
Average Volume (3M)103.52K
Market Cap
$13.10M
Enterprise Value$8.50
Total Cash (Recent Filing)$3.40B
Total Debt (Recent Filing)$3.87M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Sep 10, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.80
Shares Outstanding3,899,491
10 Day Avg. Volume167,202
30 Day Avg. Volume103,524
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)1185.36
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Potential Strategic Transformation Through Fortitude MergerFortitude brings a vertically integrated Zcash mining platform with more than 60 MW across seven sites, internal maintenance and R&D, and power flexibility. If completed, the merger could replace HeartSciences’ minimal operating base with a scaled revenue platform.
New Funding Improves Near-term Financial FlexibilityThe private placement provides operating capital ahead of the proposed merger and demonstrates financial support from the incoming strategic partner. Although limited relative to reported needs, the funding may extend execution capacity while transaction and integration work continue.
AI-ECG Product Broadens Commercial OpportunityMyoVista Insights gives HeartSciences a product platform aimed at mainstream commercial adoption and supports its differentiated AI-ECG positioning. This could create a foundation for future growth, though the pack does not yet show meaningful scale or sustained product revenue.
Bears Say
Minimal And Declining Revenue With Severe Operating LossesThe company has negligible, volatile revenue and persistently negative gross profit, operating income, and net income. This indicates that the core business is not covering its cost structure, leaving future progress dependent on a successful strategic transaction or external funding.
Persistent Cash Burn Increases Financing DependenceDeeply negative operating and free cash flow means the business is not self-funding and must rely on financing, asset sales, or a transaction to continue operations. Ongoing cash burn can constrain investment in products and increase dilution or liquidity risk.
Nasdaq Equity Noncompliance Creates Listing And Execution RiskThe equity deficiency could lead to suspension or delisting if the remediation plan is unsuccessful. Losing Nasdaq access would reduce liquidity, impair capital-market flexibility, and complicate the proposed merger, which remains subject to approvals and closing conditions.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $1.63 and its highest was $3.83 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $13.10M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Sep 10, 2026 which is in 5 days.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Heart Test Laboratories, Inc. released its earnings results on Jul 22, 2026. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.66 by $0.15.
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 3,899,491 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Heart Test Laboratories, Inc. reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.66. Following the earnings report the stock price went up 1.626%.
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heart Test Laboratories, Inc.
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
HSCS Stock 12 Month Forecast
Average Price Target
$12.00
▲(300.00% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
PAVmed
―
Tenon Medical, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
12.93% Insiders
1.08% Mutual Funds
1.68% Other Institutional Investors
82.85% Public Companies and
Individual Investors